Extraordinary Discovery: First-Ever Sighting of Live, Massive Antarctic Squid Caught on Camera
WASHINGTON--(BUSINESS WIRE)--Researchers on the National Geographic and Rolex Perpetual Planet Expedition in the Southern Ocean have recorded a history-making sighting of a three-foot-long deep-sea squid species that has never before been seen alive. The Gonatus antarcticus squid, an elusive squid found only in the frigid waters around Antarctica, was discovered on Christmas Day by the Schmidt Ocean Institute's research vessel, the R/V Falkor (too), in a surprise moment caught on camera via the research vessel's remotely operated vehicle (ROV), SuBastian. The footage, available HERE, will be broadcast in an upcoming National Geographic documentary.
Prior to the astonishing discovery, the species was only known from carcasses in fishing nets or when the squids' beaks were found in the stomach of fished marine animals. Footage of the squid shows the animal with scratches on its arms and fresh-looking sucker marks on its mantle but otherwise shows it is in good shape. Spotted at a depth of approximately 2152 meters in the Weddell Sea, researchers have not been able to confirm the squid's sex from the footage, nor age, but the discovery is a reminder of how much more there is to learn about the relatively unexplored polar regions of our world's ocean.
According to squid expert Dr. Kathrin Bolstad, who worked with marine biologist, ecophysiologist and expedition team member Manuel Novillo on the species identification, the large single central hook observed on each tentacle club clinched her confirmation that the squid was the elusive Gonatus antarcticus.
The research team also mapped several previously unexplored sites throughout the Southern Ocean, including depths that reached 4000 meters, obtaining various samples of sediment, water and biota to study the health of various Southern Ocean habitats, including abyssal plains, hydrothermal vents, troughs, canyon walls and sea ice. This work was conducted aboard the 110-meter global ocean-class R/V Falkor (too) in collaboration with the Schmidt Ocean Institute, which provided National Geographic Explorers the opportunity to leverage its state-of-the-art tools and capabilities during its maiden voyage to the Southern Ocean. Part of the National Geographic and Rolex Perpetual Planet Ocean Expedition, the mission was to provide a comprehensive scientific examination of the impact of climate and environmental change in and around the Weddell Sea, an area prioritized for marine protection and one of the few near-pristine ecosystems on the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
‘Ocean' goes deep to look at highs, lows of deep blue seas
BAKERSFIELD, Calif. (KGET) — The new National Geographic special 'Ocean with David Attenborough' offers a look at the deep blue seas through a style that almost mimics water movement. There are calm moments that discuss the beauty and wonder of the ocean world but that gives way to a tsunami of information as to the troubles facing the water world. Then it returns to another calming moment before another crash. Director Toby Nowlan explains that the structure of the production that is now available on the National Geographic Channel was to examine the overarching theme of hope and then show the juxtaposition with the damage being done to the seas. 'The theme is we are living in the age of the greatest ocean discovery, and it is David's story of ocean discovery in the last 100 years, his lifetime,' Nowlan says. 'Through that lens you are seeing this ocean of wonder where every year we are discovering things that are transforming our idea of how vital the ocean is. 'Then there is the importance of the discovery of what we are doing to the seas and how we are demolishing the seabed. Just the act of showing some of that footage for the first time, the images speak for themselves.' Pilot Peter Weber lands on NBC's 'Destination X' Nowlan points out the last big wave of the documentary looks at there is real reason to hope to protect the oceans. What the team found was that areas of the ocean that have been devastated will recover far quicker than the way dry land rebounds. The director comes to 'Ocean' having worked on a variety of projects dealing with nature. His credits include 'Our Planet,' 'Deadly Pole to Pole' and 'Wild Arabia.' In the feature-length special Attenborough draws on his lifetime of exploration and knowledge of the sea to take audiences on a journey through the planet's most spectacular undersea habitats. Attenborough investigates diverse marine ecosystems, from bustling giant kelp jungles and coral reefs to towering seamount outposts within the open ocean. These are all revealed to be intricately connected, vital to avoiding climate catastrophe, and in peril due to destructive forms of fishing. While Attenborough exposes the greatest threats to our oceans' health, he points to inspirational stories from around the world to reveal the most remarkable finding of all: If we take action now, the opportunity for marine life to recover on an unprecedented scale is well within our reach. Attenborough's more than 70 years filming the natural world has made him the world's preeminent natural historian. The English broadcaster, writer, and naturalist is best known for his award-winning BBC documentaries, including 'Life on Earth,' 'Frozen Planet,' and the 'Blue Planet' series. His work has brought the natural world into homes and classrooms, inspiring millions and motivating action towards preservation. Brandi Passante keeps looking for 'Storage Wars' treasures Nowlan stresses that the purpose of the film is to show that when it comes to the ocean, efforts to correct problems will be beneficial to every living creature or if ignored would spell total catastrophic disasters. The documentary is filled with undersea footage that is so stunning it rivals any CGI work done in feature films. Director Keith Scholey is quick to point out that there were no computer-generated images used in the film. He says the reason the movie has such a stunning look comes from the initial plans to open the documentary in theaters. 'We made a lot of feature films before and we know that is kind of a high bar,' Scholey says. 'The starting point is the cinematographer. Underwater we have the best in the world in Doug Anderson who is not only a superb diver and superb underwater naturalist, but he has an incredible sense of natural composition. 'I think one of the reasons the images look different is Doug and his eye.' Scholey knows the importance of cinematographers having worked on 'Guardians of the Galapagos,' 'Life on Our Planet' and 'Polar Bear.' 'Ballerina' dances its way to a bloody good time Both men agree that the most vital part of the production was Attenborough. Despite being one year shy of reaching 100 years old, Attenborough continues to bring energy to every project. Scholey – who has worked with Attenborough for 44 years – says, 'I met him when he was in his mid-50s, and he had it then, a huge energy and power. He has remained this person in his mid-50s because of his constant thirst for information, a constant interest in the world. 'I think it is that that keeps him modern all the time. The only way you can tell he has aged is that his accent has changed over time. Because that has happened because he has been modernizing himself.' 'Ocean with David Attenborough' debuted on the National Geographic Channel and is now available on the streaming services of Disney+ and Hulu. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT NEW YORK, June 11, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor (TKI) designed to address some of the outstanding challenges of treating ROS1+ NSCLC. It has demonstrated high response rates with durable benefit and intracranial activity and is generally well tolerated, providing a new treatment option for patients with advanced ROS1+ NSCLC. "The FDA approval of IBTROZI marks a major milestone in the evolution of targeted therapy for advanced ROS1-positive NSCLC," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "We believe one of the greatest threats to ROS1-positive lung cancer patients is disease progression, especially in the first-line setting. In pivotal trials, IBTROZI delivered high response rates with sustained durability—truly meaningful benefits for patients. With its clinically proven efficacy and safety profile, we believe IBTROZI has the potential to become a new standard for what targeted therapies can achieve in this type of lung cancer. With approvals for IBTROZI now in the U.S. and China, and additional global filings underway, we remain committed to delivering innovative therapies that help patients stay ahead of their disease." ROS1+ NSCLC is a rare and aggressive form of lung cancer, accounting for approximately 2% of new NSCLC cases, or about 3,000 new diagnoses of advanced disease annually in the U.S. The median age at diagnosis for patients with this type of lung cancer is approximately 50 years old, and the disease is more likely to occur in people who have never smoked. Brain metastases are common and a leading cause of disease progression and mortality in this population. "For people living with advanced ROS1-positive lung cancer, who tend to be diagnosed at a younger age, having another treatment option can make a real difference for them and their loved ones," said Janet Freeman-Daily, Co-Founder and President of The ROS1ders. "The approval of this new targeted therapy is a meaningful step forward for the advanced ROS1+ lung cancer community and offers hope for patients facing the added challenge of cancer spreading to the brain." The FDA approval of IBTROZI is supported by one of the largest global clinical trial programs in ROS1+ NSCLC to date, with over 300 patients enrolled in the pivotal TRUST-I and TRUST-II studies. In TRUST-I, IBTROZI achieved a confirmed overall response rate (cORR) of 90% in TKI-naïve patients. These findings were reinforced by the TRUST-II results, with a cORR of 85% in TKI-naïve patients. The median duration of response (DOR) was not yet reached for either trial, based on a cutoff date that is nearly five months later than that of the pooled TRUST-I and TRUST-II analysis published in April in the Journal of Clinical Oncology. For TRUST-I, with a median follow-up for responses of 40 months, the longest DOR was observed at 46.9 months and ongoing. For TRUST-II, with a median follow-up for responses of 19 months, the longest DOR was observed at 30.4 months and ongoing as of October 2024. Given the single-arm nature of the TRUST clinical studies, median progression-free survival (PFS) is not provided in the label. Across the pivotal studies, consistent results were also observed among patients who were previously treated with a ROS1 TKI (TKI-pretreated). In TRUST-I, treatment with IBTROZI achieved a cORR of 52% and median DOR of 13.2 months for TKI-pretreated patients, with median follow-up for responses of 33 months. In TRUST-II, treatment with IBTROZI achieved a cORR of 62%, and as of October 2024 the median DOR was 19.4 months in these patients, with a median follow-up for responses of 19 months. Brain metastases are among the most common and devastating complications in advanced ROS1+ NSCLC. IBTROZI was designed to penetrate the central nervous system (CNS) and has demonstrated consistent intracranial responses in patients with measurable brain metastases at baseline. An intracranial response was achieved in 73% of TKI-naive patients (11/15) and 63% of TKI-pretreated patients (15/24). "Patients living with advanced ROS1+ non-small cell lung cancer and their healthcare providers are in need of new treatment options," added Nathan Pennell, M.D., Ph.D., TRUST study investigator and Professor of Medicine at the Cleveland Clinic. "IBTROZI's durability of response and ability to effectively penetrate the brain, coupled with a well-characterized and manageable safety profile, further addresses these critical needs for patients. I believe this now-approved therapy offers providers and patients a promising new option for the treatment of advanced ROS1+ non-small cell lung cancer." Dr. Pennell is a compensated member of Nuvation Bio's advisory committee. IBTROZI was generally well-tolerated, with most adverse events being low grade, transient and manageable. Patients infrequently (7%) discontinued treatment due to treatment-emergent adverse events (TEAEs). The most common adverse reactions (≥20%) included diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). Overall, the majority of CNS events were mild to moderate (~90%) and resolved within days, and dose modifications due to these events were low (~5%). Approximately 90% of reported cases of dizziness were Grade 1 (mild) and transient. Liver enzyme elevations (AST 87%/ALT 85%) and QT prolongation (19%) were manageable with standard monitoring and dose modifications. IBTROZI is approved as a 600 mg once-daily oral dose, supported by a half-life of approximately 66 hours and broad tissue distribution, including the brain, enabling sustained systemic and CNS exposure. Nuvation Bio also announced the launch of NuvationConnect, a program designed to support patients prescribed IBTROZI. The program will offer financial assistance, access to resources and personalized support for eligible patients. Prescribers can learn more at or by calling 1-877-NUV-CON1 (1-877-688-2661). Conference Call & Business Update Nuvation Bio will host a conference call on June 12, 2025 at 7:30 a.m. EDT / 4:30 a.m. PDT, where company executives will provide an overview of the FDA approval of IBTROZI and our plans to now bring this medicine to patients. As a reminder to investors, the approval, together with the first commercial sale, makes the funding secured from Sagard Healthcare Partners in March fully available to the company. Nuvation Bio expects that this finances the launch of IBTROZI in full and provides further resources to continue advancing our pipeline in areas of unmet need. Investors and the general public are invited to register and listen to a live webcast of the event through the company website at Those unable to register can access the live conference call by dialing +1 833-470-1428 (U.S. toll-free) and entering access code 783971. A replay of the event will be available shortly after the conclusion. About ROS1+ NSCLC Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing CNS metastases. Despite recent progress for patients with ROS1+ NSCLC, there remains a need for more effective and tolerable treatment options. About IBTROZI IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor therapy approved for the treatment of adult patients with advanced ROS1-positive non-small cell lung cancer. Learn more at About the TRUST Clinical Program The TRUST clinical program evaluating IBTROZI for the treatment of adult patients with advanced ROS1+ NSCLC included two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, which enrolled 173 patients, and TRUST-II (NCT04919811), a global study, which enrolled 164 patients. The primary endpoint of these registrational studies is confirmed objective response rate (cORR) as assessed by an independent review committee (IRC). Key secondary endpoints include intracranial cORR, duration of response, progression-free survival, and safety. Indication IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC). IMPORTANT SAFETY INFORMATION FOR IBTROZITM (taletrectinib) WARNINGS AND PRECAUTIONS Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months). Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients. Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients. Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months). ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients. QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner. In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients. Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc. Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients. Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months). Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation. Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients. Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman. ADVERSE REACTIONS Among patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%). DRUG INTERACTIONS Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use. Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONS Pregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity. Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose. Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible. Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established. Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full Prescribing Information. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes IBTROZI (taletrectinib), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor for glioma; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit or follow the company on LinkedIn and X (@nuvationbioinc). Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, our expectations regarding IBTROZI's therapeutic potential in advanced ROS1+ NSCLC and its potential to become a new standard of care. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on May 7, 2025 under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. View source version on Contacts Media and Investor ContactsNuvation Bio Investor Contact ir@ Nuvation Bio Media Contact media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
3 hours ago
- CBS News
Elusive Antarctic squid spotted alive in the wild for the first time, captured on video
Unprecedented footage of an elusive deep-sea creature came to light this week. On an expedition through the Southern Ocean last Christmas Day, researchers discovered the Gonatus antarcticus, a mysterious species of squid known to roam the freezing waters around Antarctica but never seen alive before in its natural habitat. The crew of Schmidt Ocean Institute's research vessel, the R/V Falkor (too), encountered the squid by happenstance, according to National Geographic, which led the expedition through its nonprofit, the National Geographic Society, and on Tuesday published photos and video of the historic find. The research vessel's remotely operated vehicle, called SuBastian, captured the footage that's also set to appear in an upcoming National Geographic documentary. Presented by National Geographic Society in partnership with Rolex. A National Geographic Society expedition spotted an Antarctic gonate squid alive for the first time—helping researchers form theories around this mysterious species. — National Geographic (@NatGeo) June 10, 2025 In the first look released this week, a three-foot-long multicolored squid shimmers in pitch-dark, appearing to glow as it floats. Crew members recalled to National Geographic a cloud of green ink ejected from the animal as the machine approached, suggesting it was startled. The creature was spotted about 7,000 feet below the surface of the Weddell Sea, a remote area near the Antarctic peninsula. Researchers have yet to confirm the squid's sex or age based on the footage. Before this encounter, evidence of the Antarctic gonate squid had come exclusively in the form of carcasses caught in fishing nets or in the stomachs of its predators, National Geographic said. This particular squid was determined to be "in good shape" outside of some scratches and sucker marks. Researchers discovered the Gonatus antarcticus, a mysterious species of squid. National Geographic The Antarctic gonate is among a group of large and elusive deep-sea squid species native to the Southern Ocean, which have for the most part evaded human contact. Another, the colossal squid, was filmed alive for the first time ever in March, during a different research expedition by the Schmidt Ocean Institute around the South Sandwich Islands.
